阅读"T"叶:预测双特异抗体在多发性髓瘤中的结果
Rahul Banerjee1,2, Madhav V Dhodapkar1,2
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Blood cancer discovery
|March 12, 2026
概括
三种风险评分模型可以预测多发性骨髓瘤患者双特异性T细胞吸引剂 (TCE) 治疗的结果. 这些模型使用常规血液检测,可以增强TCE治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 双特异性T细胞吸引剂 (TCE) 疗法是多发性骨髓瘤的一种有前途的治疗方法.
- 预测患者的结果和潜在的毒性对于优化TCE治疗至关重要.
研究的目的:
- 评估三种风险评分模型的预后潜力,用于预测多发性髓瘤患者的预后结果,这些患者接受了TCE治疗.
- 评估模型预测血液毒性,感染,反应率和存活率的能力.
主要方法:
- 对278名多发性骨髓瘤患者的现实世界数据的回顾性分析,这些患者接受了TCE治疗.
- 使用患者数据验证三种预定义的风险评分模型.
主要成果:
- 这三种风险评分模型显示出预测血液毒性,感染,反应率和存活率的预后潜力.
- 这些模型很容易使用常规血液检测参数进行计算.
结论:
- 风险评分模型可以帮助预测患者的结果,并指导多发性髓瘤中TCE治疗的治疗决策.
- 这些经过验证的模型提供了一个潜在的工具,以提高双特异性T细胞吸引剂治疗的疗效和安全性.
相关概念视频
01:31Hybridoma Technology
18.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.2K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K